PTC Therapeutics financials
$64.96−1.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $360.5M | $272.6M | $164.7M | $211.0M | $178.9M | $1.18B | $213.2M | $196.8M | $186.7M | $210.1M | $307.1M | $196.6M |
| Gross profit | $340.6M | $244.5M | $157.7M | $195.2M | $167.5M | $1.16B | $196.9M | $185.9M | $171.2M | $195.4M | $277.9M | $187.1M |
| Gross margin | 94.5% | 89.7% | 95.8% | 92.5% | 93.6% | 98.9% | 92.4% | 94.5% | 91.7% | 93.0% | 90.5% | 95.2% |
| Operating income | $149.0M | $45.0M | -$70.5M | $3.0M | -$35.0M | $969.4M | -$168.1M | -$53.8M | -$40.2M | -$45.5M | -$121.9M | -$118.2M |
| Net income | $83.5M | -$2.8M | -$135.0M | $15.9M | -$64.8M | $866.6M | -$65.9M | -$106.7M | -$99.2M | -$91.6M | -$155.8M | -$133.0M |
| Net margin | 23.2% | −1.0% | −82.0% | 7.5% | −36.3% | 73.7% | −30.9% | −54.2% | −53.1% | −43.6% | −50.7% | −67.6% |
| Diluted EPS | $0.92 | $-0.03 | $-1.33 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.06 | $-1.76 |
| EBITDA | $164.9M | $61.3M | -$67.9M | $14.6M | -$27.3M | $976.7M | -$4.6M | -$45.5M | -$26.3M | $9.9M | $3.1M | -$54.6M |
| Operating cash flow | $129.1M | -$59.0M | -$34.3M | -$66.3M | -$58.3M | $870.1M | -$30.0M | -$77.0M | -$71.5M | $70.8M | -$225.3M | $110.5M |
| Free cash flow | $126.9M | -$60.2M | -$36.6M | -$69.7M | -$59.6M | $868.4M | -$33.8M | -$77.5M | -$78.8M | $61.2M | -$230.9M | $104.1M |
| Diluted shares | 92.0M | 82.5M | 101.6M | 87.1M | 78.2M | 86.4M | 77.2M | 76.9M | 76.7M | 76.5M | 75.5M | 75.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.05B | $834.0M | $984.6M | $672.6M | $1.02B | $1.48B |
| Short-term investments | $1.18B | $1.06B | $960.7M | $1.02B | $971.8M | $547.0M |
| Total debt | $597.0M | $292.9M | $292.6M | $302.8M | $305.2M | $304.6M |
| Total assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B |
| Total liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B |
| Shareholders' equity | -$165.4M | -$180.5M | -$205.3M | -$155.8M | -$206.5M | -$185.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology